Tickers — K

Kenvue is a high-margin, cash-printing consumer health titan offering an attractive 4.37% arbitrage yield ahead of its megamerger, though investors must remain hyper-vigilant regarding the catastrophic downside risks of a broken deal and the recently revived Tylenol autism litigation.

Kratos offers cash-rich exposure to the Pentagon's shift toward affordable autonomous drone swarms, but extreme valuation and near-term free cash flow burn during manufacturing expansion remain risks.